TDRs Top 5 News Stories in Psychedelics for the Week of Oct 18
Hey, big news all around in both the psych and cannabis spaces, but a red eye flight home from the MJBiz conference means there will be no post this Saturday morning… So while there will be no TOP 5, we do have some fun things in the works, including a recap of the 2021 MJBiz conference and the Top 5 will be back next weekend.
That being said, here are our favourite Top 5 stories of the week:
5. PharmaTher Engages Alcami For Clinical And Commercial Manufacturing Of Novel Ketamine Products
PharmaTher Holdings Ltd.(CNSX: PHRM) (OTCMKTS: PHRRF) has entered into an agreement with Alcami Corporation (“Alcami”), a global pharmaceutical contract development and manufacturing organization (CDMO) with extensive experience in cGMP sterile fill-finish products and handling of controlled substances, for the clinical and commercial manufacturing of the Company’s proprietary ketamine products.
4. Numinus Advances Phase 1 Trial On Proprietary Psilocybin Product And Exclusive Interview Of Its Labs Expansion
Numinus Wellness (TSXV: NUMI) announced they have finalized the study design for a Phase 1 clinical trial on a naturally derived Psilocybin extract. This major milestone advances their investigation of its first proprietary psychedelic product, which was developed using a patent-pending technology submitted to the US Patent and Trade Office.
3. atai Life Sicences Launches atai Impact
atai Life Sciences (NASDAQ: ATAI) announced the launch of its new philanthropic program, atai Impact, in line with atai Life Sciences’ vision, to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.
2. Open-label Study Of COMP360 Psilocybin Therapy For Depression In Cancer Patients
COMPASS Pathways plc (NASDAQ: CMPS) open-label study of psilocybin therapy for depression in cancer patients received favourable data this week. Within one week of a single administration of COMP360 psilocybin therapy, 50% of participants achieved remission in depression symptoms, which was sustained for the eight week follow-up period.
Small Pharma Inc. (CVE: DMT)(OTCMKTS: DMTTF) announced that following discussions with the U.K. Medicines and Healthcare products Regulatory Agency (the “MHRA”) has been granted an Innovation Passport Designation for SPL026, the lead product candidate from its pipeline of N,N-dimethyltryptamine (“DMT”) assisted therapies for the treatment of major depressive disorder (“MDD”).